OCUL Ocular Therapeutix Inc.

3.64
-0.01  -0%
Previous Close 3.65
Open 3.64
Price To Book 4.33
Market Cap 155925122
Shares 42,836,572
Volume 436,572
Short Ratio
Av. Daily Volume 545,843

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date November 10, 2019.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016. Additional Phase 3 trial to be initiated pending data from a non-significant risk device study to be initiated in 2017.
DEXTENZA
Allergic conjunctivitis
Phase 3 data due 1H 2019.
OTX-TP
Glaucoma and ocular hypertension
FDA approval announced December 3, 2018.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 2 complete. Assessing plans forward.
DEXTENZA
Dry Eye Disease
Phase 1 data due 1H 2019.
OTX-TIC
Glaucoma and ocular hypertension
Phase 1 dosing of first patient announced February 20, 2019.
OTX-TKI
Wet Age-related Macular Degeneration (AMD)

Latest News

  1. Ocular Therapeutix™ to Present at the H.C. Wainwright Global Life Sciences Conference
  2. Ocular Therapeutix™ Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
  3. Recro Pharma Falls as FDA Denies Approval to Pain Candidate
  4. Ocular Therapeutix™ Reports Election of Leslie Williams to Board of Directors
  5. Ocular Therapeutix™ to Host 2019 Research & Development Day
  6. Edited Transcript of OCUL earnings conference call or presentation 7-Mar-19 9:30pm GMT
  7. Ocular Therapeutix Inc (OCUL) Q4 2018 Earnings Conference Call Transcript
  8. Ocular Therapeutix™ Reports Fourth Quarter and Year End 2018 Financial Results and Business Update
  9. Ocular Therapeutix™ to Present at the Cowen and Company 39th Annual Health Care Conference
  10. Ocular Therapeutix™ To Report Fourth Quarter and Year End 2018 Financial Results
  11. Watch These Four Biotech Stocks Friday
  12. Ocular Therapeutix™ Prices $37.5 Million Subordinated Convertible Debt Financing
  13. Ocular Therapeutix™ Announces Dosing of First Patient in OTX-TKI (tyrosine kinase inhibitor implant) Phase 1 Clinical Trial for the Treatment of Wet Age-related Macular Degeneration (AMD)
  14. Is Ocular Therapeutix, Inc. (NASDAQ:OCUL) A Financially Sound Company?
  15. Detailed Research: Economic Perspectives on Inovalon, Merit Medical, Senseonics, Ocular Therapeutix, The Hartford Financial Services Group, and Synopsys — What Drives Growth in Today's Competitive Landscape
  16. Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza
  17. The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA
  18. Ocular Therapeutix™ Submits Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
  19. Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain
  20. Ocular Therapeutix™ Announces Completion of Debt Refinancing